CNS Pharmaceuticals Inc
NASDAQ:CNSP
NASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)

  • LAST PRICE
    0.1244
  • TODAY'S CHANGE (%)
    -0.0056 (-4.3077%)
  • Bid / Lots
    0.1160/ 30
  • Ask / Lots
    0.1200/ 49
  • Open / Previous Close
    0.1229 / 0.1300
  • Day Range
    0.1100
    0.1250
  • 52 Week Range
    0.0955
    135.0000
  • Volume
    9,891,551

Search Criteria

Click on magnifying glass icon to search

CompanyCountrySymbol

Charts

Price Comparison Graph. See accessible table below
Data delayed at least 15 minutes.

Biotechnology Industry Peers

CompanyMarket CapP/E Ratio (TTM)EPS Growth (5yr)
CNSP
CNS Pharmaceuticals Inc
6.4M
0.0x
---
BZYR
Burzynski Research Institute Inc
6.4M
-3.0x
---
ADIL
Adial Pharmaceuticals Inc
6.5M
-0.2x
---
RNAZ
Transcode Therapeutics Inc
6.6M
0.0x
---
BCLI
Brainstorm Cell Therapeutics Inc
6.6M
-0.4x
---
NLSP
NLS Pharmaceutics AG
6.7M
-0.5x
---
As of 2024-11-23

Company Information

CNS Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system (CNS). The Company's lead drug candidate, Berubicin, is a novel anthracycline and the first anthracycline to appear to cross the blood-brain barrier. Berubicin is in development for the treatment of a number of serious brain and CNS oncology indications, including glioblastoma multiforme (GBM), an aggressive and incurable form of brain cancer. In addition, the Company is advancing the development of its WP1244/WP1874 drug technology, which utilizes anthracycline and distamycin-based scaffolds to create small molecule agents. The Company is also evaluating the use of WP1244/WP1874 in the treatment of other primary brain and central nervous system cancers, as well as cancers metastatic to the brain including pancreatic, ovarian, and lymphomas.

Contact Information

Headquarters
2100 West Loop S Ste 900HOUSTON, TX, United States 77027-3522
Phone
---
Fax
---

Executives

Independent Non-Executive Chairman of the Board
Faith Charles
Chief Executive Officer, Director
John Climaco
Chief Financial Officer
Christopher Downs
Chief Science Officer
Donald Picker
Chief Medical Officer
Sandra Silberman

Ratings

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

Reports

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals

Market Cap
$6.2M
Revenue (TTM)
$0.00
Shares Outstanding
49.6M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
1.09
EPS
$-80.15
Book Value
$-35.66
P/E Ratio
0.0x
Price/Sales (TTM)
---
Price/Cash Flow (TTM)
---
Operating Margin
---
*GAAP = prior to non-GAAP analyst adjusted earnings.

Calendar

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.